Pareek Manan, Mortensen Martin Bødtker, Løfgren Bo, Nielsen Mette Lundgren, Olsen Michael Hecht, Andersen Niels Holmark
Ugeskr Laeger. 2018 Feb 5;180(6).
This review summarizes the cardiovascular non-inferiority trials of novel antidiabetic drugs performed since 2008, when regulatory agencies started mandating thorough examination of their cardiovascular safety. So far, eight randomized trials on three different drug classes have been completed. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce cardiovascular risk and possibly mortality, while dipeptidyl dipeptidase-4 inhibitors may increase the risk of heart failure. A brief discussion of potential mechanisms and clinical implications is provided.
本综述总结了自2008年以来开展的新型抗糖尿病药物的心血管非劣效性试验，当时监管机构开始强制要求全面检查其心血管安全性。到目前为止，已完成了针对三种不同药物类别的八项随机试验。钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂可能会降低心血管风险，甚至可能降低死亡率，而二肽基肽酶4抑制剂可能会增加心力衰竭的风险。本文还对潜在机制和临床意义进行了简要讨论。
